FDA approves Pegcetacoplan-Empaveli to treat rare kidney disease

PegcetacoplanAs a targeted complementC3's biologic drug will be approved by the US on 2025 7month28 Approved by the China Food and Drug Administration (FDA) for the treatment of two extremely rare and serious kidney diseases - C3 glomerulopathy (C3 glomerulopathy span>C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which marks an important advance in the field of renal disease treatment. Previously, Empaveli has been approved for the rare blood system disease paroxysmal nocturnal hemoglobinuria (PNH), but this new approval is an expanded indication for kidney disease, filling a clinical need that has been unmet for many years.

Both C3G and IC-MPGN are extremely rare complement-mediated kidney diseases, and their pathological mechanisms are related to abnormal activation of the complement system, leading to intraglomerular C3 deposition, inflammation, and gradual deterioration of renal function. Traditional treatments are often limited to supportive care, and many patients eventually progress to renal failure and require long-term dialysis or kidney transplantation. The approval of Empaveli is based on its ability to significantly inhibit the excessive activation of complement C3, thereby reducing pathological immune responses, which is innovative in the history of the treatment of this type of disease.

At the heart of this approval is data support from the Phase 3VALIANT trial. This randomized, controlled, multicenter clinical trial evaluated the efficacy and safety of Pegcetacoplan in patients 12 years of age and older, focusing on three key indicators: urinary protein excretion (proteinuria), renal function stability, and the degree of C3 deposition. The results showed that compared with the control group, patients treated with Empaveli had significantly reduced proteinuria, glomerular filtration function stabilized, and renal C3 deposition in most patients was significantly reduced or even completely eliminated, which are important biomarkers for measuring the progression of kidney disease.

In terms of specific cases, news reports and medical materials have repeatedly emphasized thatEmpaveli's "transformational" efficacy in this population. A nephrology expert in charge of the trial pointed out that under previous standard treatments, patients with C3G and IC-MPGN faced a very high risk of renal failure, especially young patients and adolescents, whose disease progression was often rapid and difficult to control. The approval of Empaveli provides these patients for the first time with a targeted treatment option that has undergone rigorous regulatory review.

References: https://investors.apellis.com/news-releases/news-release-details/fda-approves-apellis-empavelir-pegcetacoplan-first-c3g-and